Department of Anesthesiology, Graduate School of Medicine, University of Tokyo, Tokyo, Japan.
Interdepartmental Division of Critical Care Medicine, University of Toronto, Toronto, Ontario, Canada.
JAMA Netw Open. 2019 Jul 3;2(7):e198116. doi: 10.1001/jamanetworkopen.2019.8116.
A number of interventions are available to manage patients with moderate to severe acute respiratory distress syndrome (ARDS). However, the associations of currently available ventilatory strategies and adjunctive therapies with mortality are uncertain.
To compare and rank different therapeutic strategies to identify the best intervention associated with a reduction in mortality in adult patients with moderate to severe ARDS.
An electronic search of MEDLINE, MEDLINE In-Process/ePubs Ahead of Print, Embase, Cochrane Controlled Clinical Trial Register (Central), PubMed, and CINAHL was conducted, from database inception to May 29, 2019.
Randomized clinical trials of interventions for adults with moderate to severe ARDS that used lung protective ventilation. No language restrictions were applied.
Data were independently extracted by 2 reviewers and synthesized with Bayesian random-effects network meta-analyses.
The primary outcome was 28-day mortality. Barotrauma was a secondary outcome.
Among 25 randomized clinical trials evaluating 9 interventions, 2686 of 7743 patients (34.6%) died within 28 days. Compared with lung protective ventilation alone, prone positioning and venovenous extracorporeal membrane oxygenation were associated with significantly lower 28-day mortality (prone positioning: risk ratio, 0.69; 95% credible interval, 0.48-0.99; low quality of evidence; venovenous extracorporeal membrane oxygenation: risk ratio, 0.60; 95% credible interval, 0.38-0.93; moderate quality of evidence). These 2 interventions had the highest ranking probabilities, although they were not significantly different from each other. Among 18 trials reporting on barotrauma, 448 of 6258 patients (7.2%) experienced this secondary outcome. No intervention was superior to any other in reducing barotrauma, and each represented low to very low quality of evidence.
This network meta-analysis supports the use of prone positioning and venovenous extracorporeal membrane oxygenation in addition to lung protective ventilation in patients with ARDS. Moreover, venovenous extracorporeal membrane oxygenation may be considered as an early strategy for adults with severe ARDS receiving lung protective ventilation.
有许多干预措施可用于治疗中重度急性呼吸窘迫综合征(ARDS)患者。然而,目前可用的通气策略和辅助治疗与死亡率的关系尚不确定。
比较和排名不同的治疗策略,以确定与降低中重度 ARDS 成人死亡率相关的最佳干预措施。
对 MEDLINE、MEDLINE In-Process/ePubs Ahead of Print、Embase、Cochrane 对照临床试验注册中心(Central)、PubMed 和 CINAHL 进行了电子检索,检索时间从数据库建立到 2019 年 5 月 29 日。
使用肺保护性通气治疗中重度 ARDS 成人的干预措施的随机临床试验。未应用语言限制。
由 2 位评审员独立提取数据,并通过贝叶斯随机效应网络荟萃分析进行综合。
主要结局为 28 天死亡率。气压伤是次要结局。
在 25 项评估 9 项干预措施的随机临床试验中,7743 例患者中有 2686 例(34.6%)在 28 天内死亡。与单独使用肺保护性通气相比,俯卧位和静脉-静脉体外膜肺氧合与 28 天死亡率显著降低相关(俯卧位:风险比,0.69;95%可信区间,0.48-0.99;低质量证据;静脉-静脉体外膜肺氧合:风险比,0.60;95%可信区间,0.38-0.93;中等质量证据)。这两种干预措施的排名概率最高,尽管它们彼此之间没有显著差异。在 18 项报告气压伤的试验中,6258 例患者中有 448 例(7.2%)发生了这一次要结局。没有任何干预措施在降低气压伤方面优于其他任何干预措施,且每一种干预措施的证据质量均为低至极低。
本网络荟萃分析支持在 ARDS 患者中除肺保护性通气外,还使用俯卧位和静脉-静脉体外膜肺氧合。此外,对于接受肺保护性通气的严重 ARDS 成人,可考虑将静脉-静脉体外膜肺氧合作为早期策略。